Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SuperGen, a pharmaceutical company engaged in the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation, has reported total revenues of $15.28m for the fourth quarter ended 31 December 2010, compared to $11.97m for the same period in 2009.
Subscribe to our email newsletter
SuperGen has posted a net income of $6.75m for the fourth quarter of 2010, compared to $2.34m for the same period in 2009.
SuperGen’ income from operations was $6.49m, compared to $1.36m for the same period in 2009.
For the full-year ended 31 December 2010, the company posted a net income of $16.27m, compared to $4.74m for the same period in 2009.
Total revenues for the full-year of 2010 were $52.97m, compared to $41.25m for the same period in 2009.
The company’s income from operations was $15.89m, compared to $3.17m in the same period of 2009.
SuperGen president and CEO James Manuso said during 2010, their clinical-stage drugs, amuvatinib (MP-470) and SGI-110, advanced in the clinic.
"Our multi-year discovery and development collaboration with GlaxoSmithKline (GSK) is progressing on schedule," Manuso said.
"We believe that our operating funds are sufficient to execute the current and planned discovery and development initiatives over several years."